Experienced in Obesity

Dr. Jane L. Rohlf

Internal Medicine
708 Chambers St, 
Trenton, NJ 
Experienced in Obesity
708 Chambers St, 
Trenton, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jane Rohlf is a primary care provider, practicing in Internal Medicine in Trenton, New Jersey. Dr. Rohlf is rated as an Experienced provider by MediFind in the treatment of Obesity. Her top areas of expertise are Maturity Onset Diabetes of the Young, Obesity, and Type 2 Diabetes (T2D).

Her clinical research consists of participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 4 clinical trials in the study of Obesity.

Specialties
Internal Medicine
Licenses
Internal Medicine in NJ
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareFirst
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

708 Chambers St, Trenton, NJ 08611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 in Adults With Mixed Dyslipidemia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 in Adults With Mixed Dyslipidemia
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drug: LY3561774
Study Phase: Phase 2
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drugs: LY3502970, Dulaglutide
Study Phase: Phase 2
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drug: LY3502970
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Semaglutide
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: June 12, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus
A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: August 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials
Similar Doctors
Elite in Obesity
Dr. Steven B. Heymsfield
Internal Medicine
Elite in Obesity
Dr. Steven B. Heymsfield
Internal Medicine
1090 Amsterdam Ave, 14 Th Floor Obesity Research, 
New York, NY 
 (57.8 miles away)
732-407-3404
Languages Spoken:
English
See accepted insurances

Steven Heymsfield is a primary care provider, practicing in Internal Medicine in New York, New York. Dr. Heymsfield is rated as a Distinguished provider by MediFind in the treatment of Obesity. His top areas of expertise are Obesity, Muscle Atrophy, Malnutrition, Transcobalamin Deficiency, and Gastric Bypass.

Distinguished in Obesity
Dr. Melanie R. Jay
Internal Medicine
Distinguished in Obesity
Dr. Melanie R. Jay
Internal Medicine
227 Madison St, Medicine, 4th Fl, Gouverneur Healthcare Services, 
New York, NY 
 (52.5 miles away)
212-238-7614
Languages Spoken:
English

Melanie Jay is a primary care provider, practicing in Internal Medicine in New York, New York. Dr. Jay is rated as an Advanced provider by MediFind in the treatment of Obesity. Her top areas of expertise are Obesity, COVID-19, Obesity in Children, Type 2 Diabetes (T2D), and Sleeve Gastrectomy.

Distinguished in Obesity
Dr. Rameck R. Hunt
Internal Medicine | Bariatric Medicine
Distinguished in Obesity
Dr. Rameck R. Hunt
Internal Medicine | Bariatric Medicine

Penn Princeton Primary Care Medical Arts Pavilion

5 Plainsboro Road, Medical Arts Pavilion, Suite 300, 
Plainsboro, NJ 
 (10.7 miles away)
609-853-7272
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rameck Hunt is an Internal Medicine specialist and a Bariatric Medicine provider in Plainsboro, New Jersey. Dr. Hunt is rated as an Advanced provider by MediFind in the treatment of Obesity. His top areas of expertise are Obesity, Obesity in Children, Hypertension, and Type 2 Diabetes (T2D).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rohlf's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile